RT Journal Article
SR Electronic
T1 Longitudinal analysis of antibody responses to the Pfizer BNT162b2 vaccine in Patients Undergoing Maintenance Hemodialysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.20.21260849
DO 10.1101/2021.07.20.21260849
A1 André Weigert
A1 Marie-Louise Bergman
A1 Ligia Gonçalves
A1 Iolanda Godinho
A1 Nádia Duarte
A1 Rita Abrantes
A1 Patrícia Borges
A1 Ana Brennand
A1 Vanessa Malheiro
A1 Paula Matoso
A1 Onome Akpogheneta
A1 Lindsay Kosack
A1 Pedro Cruz
A1 Estela Nogueira
A1 Magda Pereira
A1 Ana Ferreira
A1 Marco Marques
A1 Telmo Nunes
A1 João Viana
A1 Jocelyne Demengeot
A1 Carlos Penha-Gonçalves
YR 2021
UL http://medrxiv.org/content/early/2021/07/22/2021.07.20.21260849.abstract
AB Background and objectives Patients undergoing hemodialysis are at higher risk of developing severe complications upon SARS-CoV-2 infection and were prioritized in the Portuguese vaccination campaign. Immunogenicity of COVID-19 vaccines in hemodialyzed patients was not addressed by the phase 3 clinical trials leading to their emergency approval.Design, setting, participants, and measurements We performed a prospective, longitudinal, cohort analysis of 156 hemodialyzed patients and 143 age-matched controls scheduled for BTN162b2 vaccine. Excluded from analysis were five patients previously diagnosed with SARS-CoV-2, three sero-positive for anti-SARS-CoV-2 N, two dropouts and two deaths. ELISA was used to quantify anti-full-length Spike IgG, IgM and IgA levels in sera collected at day of the first vaccine dose (t0); 3 weeks later (day of the second dose, t1); and 3 weeks after the second inoculation (t2).Results Seroconversion after the first vaccine dose (t1) was remarkably low in patients, with positivity for anti-spike IgG, IgM and IgA antibodies of 29.4%, 12% and 41%, respectively. The second vaccine dose raised seroconversion to 90.9% and 83.9% for IgG and IgA, respectively, while IgM positivity remained unchanged. At t1 the anti-Spike IgG level was significantly lower in patients with ages below 70 years when compared to age-matched controls, showing a profile similar to aged individuals (above 70 years). Immunosuppression was associated with lower antibody responses along the vaccine schedule (p=0.005 at t1; p=0.008 at t2). Noteworthy, previous unresponsiveness to hepatitis B vaccination (75/129, 58% of patients negative for anti-HBs antibodies) did not correlate with humoral unresponsiveness to BTN162b2. Other clinical and laboratory parameters had marginal correlations with response to vaccination.Conclusions The large majority of hemodialyzed patients showed IgG seroconversion upon BNT162b2 mRNA vaccination but a sizable proportion of patients presented poor responses. These results support further investigation into the relationship between vaccination, serologic response and host protection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementPart of the laboratory evaluation was possible due to the use of research Funds from Davita Portugal. This work benefited from COVID-19 emergency funds 2020 from Calouste Gulbenkian Foundation and from Oeiras and Almeirim city councils. It was also supported by the Science and Technology Foundation, Ministry of Education and Science (FCT, Portugal) through the Project 754-Research4COVID-19 2nd edition.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics committee of Davita in Portugal in compliance with the Declaration of Helsinki, and follows international and national guidelines for health data protection. All participants provided informed consent to take part in the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request